1156 related articles for article (PubMed ID: 21225098)
1. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
[TBL] [Abstract][Full Text] [Related]
2. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
Friedman RJ; Dahl OE; Rosencher N; Caprini JA; Kurth AA; Francis CW; Clemens A; Hantel S; Schnee JM; Eriksson BI;
Thromb Res; 2010 Sep; 126(3):175-82. PubMed ID: 20434759
[TBL] [Abstract][Full Text] [Related]
3. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Huisman MV; Quinlan DJ; Dahl OE; Schulman S
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
[TBL] [Abstract][Full Text] [Related]
4. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Eriksson BI; Borris LC; Friedman RJ; Haas S; Huisman MV; Kakkar AK; Bandel TJ; Beckmann H; Muehlhofer E; Misselwitz F; Geerts W;
N Engl J Med; 2008 Jun; 358(26):2765-75. PubMed ID: 18579811
[TBL] [Abstract][Full Text] [Related]
5. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
Eriksson BI; Dahl OE; Rosencher N; Kurth AA; van Dijk CN; Frostick SP; Prins MH; Hettiarachchi R; Hantel S; Schnee J; Büller HR;
Lancet; 2007 Sep; 370(9591):949-56. PubMed ID: 17869635
[TBL] [Abstract][Full Text] [Related]
6. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Lassen MR; Ageno W; Borris LC; Lieberman JR; Rosencher N; Bandel TJ; Misselwitz F; Turpie AG;
N Engl J Med; 2008 Jun; 358(26):2776-86. PubMed ID: 18579812
[TBL] [Abstract][Full Text] [Related]
7. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
Weitz JI; Cao C; Eriksson BI; Fisher W; Kupfer S; Raskob G; Spaeder J; Turpie AG
Thromb Haemost; 2010 Dec; 104(6):1150-7. PubMed ID: 20886185
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.
Eriksson BI; Friedman RJ
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():25S-31S. PubMed ID: 19648146
[TBL] [Abstract][Full Text] [Related]
9. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
[TBL] [Abstract][Full Text] [Related]
11. Thromboprophylaxis with dabigatran after total hip arthroplasty in Indian patients: A subanalysis of a double-blind, double-dummy, randomized RE-NOVATE II study.
Malhotra R; Babhulkar S; Sanjib KB; Clemens A; Dadi A; Iyer R; Kamath S; Mody B; Mutha S; Reddy G; Shah V; Shah V; Shetty N; Tapasvi S; Wadhwa M
Asian J Surg; 2017 Apr; 40(2):145-151. PubMed ID: 27143213
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
Wolowacz SE; Roskell NS; Plumb JM; Caprini JA; Eriksson BI
Thromb Haemost; 2009 Jan; 101(1):77-85. PubMed ID: 19132192
[TBL] [Abstract][Full Text] [Related]
13. Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials.
Nieto JA; Espada NG; Merino RG; González TC
Thromb Res; 2012 Aug; 130(2):183-91. PubMed ID: 22425218
[TBL] [Abstract][Full Text] [Related]
14. Interpretation of endpoints in a network meta-analysis of new oral anticoagulants following total hip or total knee replacement surgery.
Harenberg J; Marx S; Dahl OE; Marder VJ; Schulze A; Wehling M; Weiss C
Thromb Haemost; 2012 Nov; 108(5):903-12. PubMed ID: 23014668
[TBL] [Abstract][Full Text] [Related]
15. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
; Ginsberg JS; Davidson BL; Comp PC; Francis CW; Friedman RJ; Huo MH; Lieberman JR; Muntz JE; Raskob GE; Clements ML; Hantel S; Schnee JM; Caprini JA
J Arthroplasty; 2009 Jan; 24(1):1-9. PubMed ID: 18534438
[TBL] [Abstract][Full Text] [Related]
16. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI; Borris LC; Dahl OE; Haas S; Huisman MV; Kakkar AK; Muehlhofer E; Dierig C; Misselwitz F; Kälebo P;
Circulation; 2006 Nov; 114(22):2374-81. PubMed ID: 17116766
[TBL] [Abstract][Full Text] [Related]
17. Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis.
Eriksson BI; Dahl OE; Feuring M; Clemens A; Noack H; Hantel S; Friedman RJ; Huo M
Thromb Res; 2012 Nov; 130(5):818-20. PubMed ID: 22840686
[TBL] [Abstract][Full Text] [Related]
18. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Schulman S; Kakkar AK; Goldhaber SZ; Schellong S; Eriksson H; Mismetti P; Christiansen AV; Friedman J; Le Maulf F; Peter N; Kearon C;
Circulation; 2014 Feb; 129(7):764-72. PubMed ID: 24344086
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
Turpie AG; Lassen MR; Eriksson BI; Gent M; Berkowitz SD; Misselwitz F; Bandel TJ; Homering M; Westermeier T; Kakkar AK
Thromb Haemost; 2011 Mar; 105(3):444-53. PubMed ID: 21136019
[TBL] [Abstract][Full Text] [Related]
20. Dabigatran: new drug. Continue to use heparin, a better-known option.
Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
